Analysis of DICE Therapeutics Inc. (DICE)’s performance, earnings and valuation

At the time of writing, DICE Therapeutics Inc. [DICE] stock is trading at $33.47, up 0.19%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DICE shares have gain 4.37% over the last week, with a monthly amount drifted -3.85%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

On 9, November 2022, DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights. In a post published today on Yahoo Finance, Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasis.

From an analyst’s perspective:

DICE Therapeutics Inc. [NASDAQ: DICE] stock has seen the most recent analyst activity on November 15, 2022, when Guggenheim initiated its Buy rating and assigned the stock a price target of $65. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on September 14, 2022, and set its price target to $36. On September 07, 2022, Stifel initiated with a Buy rating and assigned a price target of $37 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $40 on July 18, 2022. SVB Leerink initiated its recommendation with a Outperform and recommended $46 as its price target on October 11, 2021. Evercore ISI started tracking with a Outperform rating for this stock on October 11, 2021, and assigned it a price target of $60. In a note dated October 11, 2021, BofA Securities initiated an Buy rating and iterated a target price of $41 on this stock.

For the past year, the stock price of DICE Therapeutics Inc. fluctuated between $12.64 and $45.99. Currently, Wall Street analysts expect the stock to reach $64.43 within the next 12 months. DICE Therapeutics Inc. [NASDAQ: DICE] shares were valued at $33.47 at the most recent close of the market. An investor can expect a potential return of 92.5% based on the average DICE price forecast.

Analyzing the DICE fundamentals

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.92 points at the first support level, and at 32.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.52, and for the 2nd resistance point, it is at 35.56.

DICE Therapeutics Inc. [DICE] reported earnings per share of -$0.58 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.55/share, meaning a difference of -$0.03 and a surprise factor of -5.50%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.5 per share as compared to estimates of -$0.54 per share, a difference of $0.04 representing a surprise of 7.40%.

Ratios To Look Out For

It is important to note that DICE Therapeutics Inc. [NASDAQ:DICE] has a current ratio of 23.00.

Transactions by insiders

We now turn our attention to insider trading, which in the past 3 months has resulted in 1 insider buyings of 1,640,000 shares and 0 insider sellings of 0 shares. Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Oct 17 when 1.64 million shares were purchased.